Islam, Gender, Intersektionalität: Bildungswege junger Frauen in der Schweiz

Wie wirkt sich der aktuelle Islamdiskurs auf Bildungsbiografien junger Secondas aus? Wie beeinflussen unterschiedliche Differenzkategorien wie beispielsweise Gender und Religion die Bildungsbiografien? Und wirken diese Kategorien intersektionell? Die Autorin zeigt auf, wie unterschiedlich junge Secondas aus der Schweiz mit der Herausforderung umgehen, als religiös orientierte muslimische Frauen in einem tendenziell islamkritischen Umfeld bildungsbiografisch zu bestehen. Sie verdeutlicht die bestehenden Bildungsbarrieren samt den unterschiedlichen Taktiken, diese zu umgehen. Auf dieser Grundlage diskutiert sie, inwiefern Religion dabei als intersektionale, interdependente Analysekategorie gefasst werden kann

Modulation of drug sensitivity in yeast cells by the ATP‐binding domain of human DNA topoisomerase IIα

Epipodophyllotoxins are effective antitumour drugs that trap eukaryotic DNA topoisomerase II in a covalent complex with DNA. Based on DNA cleavage assays, the mode of interaction of these drugs was proposed to involve amino acid residues of the catalytic site. An in vitro binding study, however, revealed two potential binding sites for etoposide within human DNA topoisomerase IIα (htopoIIα), one in the catalytic core of the enzyme and one in the ATP‐binding N‐terminal domain. Here we have tested how N‐terminal mutations that reduce the affinity of the site for etoposide or ATP affect the sensitivity of yeast cells to etoposide. Surprisingly, when introduced into full‐length enzymes, mutations that lower the drug binding capacity of the N‐terminal domain in vitro render yeast more sensitive to epipodophyllotoxins. Consistently, when the htopoIIα N‐terminal domain alone is overexpressed in the presence of yeast topoII, cells become more resistant to etoposide. Point mutations that weaken etoposide binding eliminate this resistance phenotype. We argue that the N‐terminal ATP‐binding pocket competes with the active site of the holoenzyme for binding etoposide both in cis and in trans with different outcomes, suggesting that each topoisomerase II monomer has two non‐equivalent drug‐binding site

Arbeit am Fall mit angehenden Lehrpersonen – Eine Rekonstruktion unterschiedlicher Reflexionsverständnisse

Wie kann der Aufbau eines reflexiv-forschenden Habitus als eines konstitutiven Bestandteils pädagogischer Professionalität an pädagogischen Hochschulen gefördert werden? Diese Frage spielt im aktuellen Diskurs über die Ausbildung professioneller Lehrpersonen eine zentrale Rolle. Angehende Lehrpersonen, die «Reflexionskompetenz» aufbauen, entwickeln ein Bewusstsein dafür, dass professionelles Handeln nicht vollständig standardisierbar oder routinisierbar sein kann und dass die im schulischen Alltag gefällten Entscheidungen kritisch reflektiert und begründet werden müssen. Zur Einübung dieser reflexiven Kompetenz erhalten die Studierenden des Instituts für Vorschul- und Primarstufe der Pädagogischen Hochschule Bern (PH Bern) seit 2008 den Auftrag, im Rahmen einer Fallarbeit eine im Praktikum erlebte Situation zu protokollieren und anschliessend methodisch angeleitet zu analysieren. 45 Fallarbeiten wurden in einer Studie auf das Professionsverständnis von Studierenden hin untersucht, das der Reflexion von Praxissituationen zugrunde liegt. Basierend auf der Untersuchung konnten drei Typen von Professionsverständnissen rekonstruiert werden: die Lehrperson als reflexivprofessionalisierte Praktikerin, als soziotechnokratische Perfektionistin und als charismatische Meisterin. Diese Typologie wird im Beitrag erläutert und hinsichtlich des Professionalisierungsdiskurses diskutiert. Daran anschliessend werden mögliche Konsequenzen für die Ausbildung an pädagogischen Hochschulen skizziert

Auskultationsbefunde bei Pferden

Aufarbeitung und Praxisbeispiele für die online Lehrplattform EquiSur

Scale-up of Digital Innovations in Health Care: Expert Commentary on Enablers and Barriers

Health care delivery is undergoing a rapid change from traditional processes toward the use of digital health interventions and personalized medicine. This movement has been accelerated by the COVID-19 crisis as a response to the need to guarantee access to health care services while reducing the risk of contagion. Digital health scale-up is now also vital to achieve population-wide impact: it will only accomplish sustainable effects if and when deployed into regular health care delivery services. The question of how sustainable digital health scale-up can be successfully achieved has, however, not yet been sufficiently resolved. This paper identifies and discusses enablers and barriers for scaling up digital health innovations. The results discussed in this paper were gathered by scientists and representatives of public bodies as well as patient organizations at an international workshop on scaling up digital health innovations. Results are explored in the context of prior research and implications for future work in achieving large-scale implementations that will benefit the population as a whole

Expert Commentary on Enablers and Barriers

©Hannes Schlieter, Lisa A Marsch, Diane Whitehouse, Lena Otto, Ana Rita Londral, Gisbert Wilhelm Teepe, Martin Benedict, Joseph Ollier, Tom Ulmer, Nathalie Gasser, Sabine Ultsch, Bastian Wollschlaeger, Tobias Kowatsch. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 11.03.2022.Health care delivery is undergoing a rapid change from traditional processes toward the use of digital health interventions and personalized medicine. This movement has been accelerated by the COVID-19 crisis as a response to the need to guarantee access to health care services while reducing the risk of contagion. Digital health scale-up is now also vital to achieve population-wide impact: it will only accomplish sustainable effects if and when deployed into regular health care delivery services. The question of how sustainable digital health scale-up can be successfully achieved has, however, not yet been sufficiently resolved. This paper identifies and discusses enablers and barriers for scaling up digital health innovations. The results discussed in this paper were gathered by scientists and representatives of public bodies as well as patient organizations at an international workshop on scaling up digital health innovations. Results are explored in the context of prior research and implications for future work in achieving large-scale implementations that will benefit the population as a whole.publishersversionpublishe

Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification:

BACKGROUND: Over the last few decades, new synthetic insulin analogues have been developed. Their measurement is of prime importance in the investigation of hypoglycaemia, but their quantification is hampered by variable cross-reactivity with many insulin assays. For clinical analysis, it has now become essential to know the potential cross-reactivity of analogues of interest. METHODS: In this work, we performed an extensive study of insulin analogue cross-reactivity using numerous human insulin immunoassays. We investigated the cross-reactivity of five analogues (lispro, aspart, glulisine, glargine, detemir) and two glargine metabolites (M1 and M2) with 16 commercial human insulin immunoassays as a function of concentration. RESULTS: The cross-reactivity values for insulin analogues or glargine metabolites ranged from 0% to 264%. Four assays were more specific to human insulin, resulting in negligible cross-reactivity with the analogues. However, none of the 16 assays was completely free of cross-reactivity with analogues or metabolites. The results show that analogue cross-reactivity, which varies to a large degree, is far from negligible, and should not be overlooked in clinical investigations. CONCLUSIONS: This study has established the cross-reactivity of five insulin analogues and two glargine metabolites using 16 immunoassays to facilitate the choice of the immunoassay(s) and to provide sensitive and specific analyses in clinical routine or investigation

Global Carbon Budget 2022

Accurate assessment of anthropogenic carbon dioxide (CO$_2$) emissions and their redistribution among the atmosphere, ocean, and terrestrial biosphere in a changing climate is critical to better understand the global carbon cycle, support the development of climate policies, and project future climate change. Here we describe and synthesize data sets and methodologies to quantify the five major components of the global carbon budget and their uncertainties. Fossil CO$_2$ emissions (E$_{FOS}$) are based on energy statistics and cement production data, while emissions from land-use change (E$_{LUC}$), mainly deforestation, are based on land use and land-use change data and bookkeeping models. Atmospheric CO$_2$ concentration is measured directly, and its growth rate (G$_{ATM}$) is computed from the annual changes in concentration. The ocean CO$_2$ sink (S$_{OCEAN}$) is estimated with global ocean biogeochemistry models and observation-based data products. The terrestrial CO$_2$ sink (S$_{LAND}$) is estimated with dynamic global vegetation models. The resulting carbon budget imbalance (B$_{IM}$), the difference between the estimated total emissions and the estimated changes in the atmosphere, ocean, and terrestrial biosphere, is a measure of imperfect data and understanding of the contemporary carbon cycle. All uncertainties are reported as ±1σ. For the year 2021, E$_{FOS}$ increased by 5.1 % relative to 2020, with fossil emissions at 10.1 ± 0.5 GtC yr$^{−1}$ (9.9 ± 0.5 GtC yr$^{−1}$ when the cement carbonation sink is included), and E$_{LUC}$ was 1.1 ± 0.7 GtC yr$^{−1}$, for a total anthropogenic CO$_2$ emission (including the cement carbonation sink) of 10.9 ± 0.8 GtC yr$^{−1}$ (40.0 ± 2.9 GtCO$_2$). Also, for 2021, G$_{ATM}$ was 5.2 ± 0.2 GtC yr$^{−1}$ (2.5 ± 0.1 ppm yr$^{−1}$), S$_{OCEAN}$ was 2.9  ± 0.4 GtC yr$^{−1}$, and S$_{LAND}$ was 3.5 ± 0.9 GtC yr$^{−1}$, with a B$_{IM}$ of −0.6 GtC yr$^{−1}$ (i.e. the total estimated sources were too low or sinks were too high). The global atmospheric CO$_2$ concentration averaged over 2021 reached 414.71 ± 0.1 ppm. Preliminary data for 2022 suggest an increase in E$_{FOS}$ relative to 2021 of +1.0 % (0.1 % to 1.9 %) globally and atmospheric CO$_2$ concentration reaching 417.2 ppm, more than 50 % above pre-industrial levels (around 278 ppm). Overall, the mean and trend in the components of the global carbon budget are consistently estimated over the period 1959–2021, but discrepancies of up to 1 GtC yr$^{−1}$ persist for the representation of annual to semi-decadal variability in CO$_2$ fluxes. Comparison of estimates from multiple approaches and observations shows (1) a persistent large uncertainty in the estimate of land-use change emissions, (2) a low agreement between the different methods on the magnitude of the land CO$_2$ flux in the northern extratropics, and (3) a discrepancy between the different methods on the strength of the ocean sink over the last decade. This living data update documents changes in the methods and data sets used in this new global carbon budget and the progress in understanding of the global carbon cycle compared with previous publications of this data set. The data presented in this work are available at https://doi.org/10.18160/GCP-2022 (Friedlingstein et al., 2022b)

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.

peer reviewedDespite advances in COVID-19 management, identifying patients evolving toward death remains challenging. To identify early predictors of mortality within 60 days of symptom onset (DSO), we performed immunovirological assessments on plasma from 279 individuals. On samples collected at DSO11 in a discovery cohort, high severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA (vRNA), low receptor binding domain–specific immunoglobulin G and antibody-dependent cellular cytotoxicity, and elevated cytokines and tissue injury markers were strongly associated with mortality, including in patients on mechanical ventilation. A three-variable model of vRNA, with predefined adjustment by age and sex, robustly identified patients with fatal outcome (adjusted hazard ratio for log-transformed vRNA = 3.5). This model remained robust in independent validation and confirmation cohorts. Since plasma vRNA’s predictive accuracy was maintained at earlier time points, its quantitation can help us understand disease heterogeneity and identify patients who may benefit from new therapies